Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Royalty Pharma Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Royalty Pharma kazanç ve gelirin sırasıyla yıllık 11.4% ve 6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 12.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 23.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

11.4%

Kazanç büyüme oranı

12.2%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.7%
Gelir büyüme oranı	6.0%
Gelecekteki özkaynak getirisi	23.7%
Analist kapsamı	Good
Son güncelleme	13 Aug 2024

Gelecekteki son büyüme güncellemeleri

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12

Recent updates

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

May 11

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Apr 28

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Apr 25

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Apr 04

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Feb 22

Royalty Pharma: Solid Operational Performance

Feb 19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Jan 31

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Jan 22

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Dec 26

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Aug 18

Royalty Pharma declares $0.19 dividend

Jul 15

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:RPRX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	3,058	933	3,004	2,889	5
12/31/2025	2,839	908	2,698	2,616	5
12/31/2024	2,663	634	2,585	2,467	5
6/30/2024	2,238	673	401	2,669	N/A
3/31/2024	2,239	799	1,019	2,619	N/A
12/31/2023	2,355	1,135	872	2,988	N/A
9/30/2023	2,324	184	1,422	2,785	N/A
6/30/2023	2,361	255	522	2,750	N/A
3/31/2023	2,359	332	374	2,718	N/A
12/31/2022	2,237	43	402	2,144	N/A
9/30/2022	2,247	507	401	2,064	N/A
6/30/2022	2,259	466	312	1,995	N/A
3/31/2022	2,278	602	263	1,952	N/A
12/31/2021	2,289	620	-174	2,018	N/A
9/30/2021	2,286	783	-732	2,093	N/A
6/30/2021	2,239	972	-159	2,132	N/A
3/31/2021	2,195	493	-496	2,090	N/A
12/31/2020	2,122	495	-148	2,035	N/A
9/30/2020	2,008	1,745	104	1,947	N/A
6/30/2020	1,934	1,863	793	1,858	N/A
3/31/2020	1,880	2,052	1,093	1,705	N/A
12/31/2019	1,814	2,349	-54	1,667	N/A
12/31/2018	1,795	1,378	1,349	1,618	N/A
12/31/2017	1,598	1,210	N/A	1,418	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: RPRX 'nin tahmini kazanç büyümesi (yıllık 11.4% ) tasarruf oranının ( 2.5% ) üzerindedir.

Kazançlar ve Piyasa: RPRX şirketinin kazançlarının (yıllık 11.4% ) US pazarından (yıllık 15.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: RPRX şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: RPRX şirketinin gelirinin (yıllık 6% ) US pazarından (yıllık 8.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: RPRX şirketinin gelirinin (yıllık 6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: RPRX 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 23.7 %)

Royalty Pharma Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 33%

Consensus EPS estimates fall by 10%

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Consensus EPS estimates increase by 79%

Consensus EPS estimates increase by 68%

Consensus EPS estimates increase by 94%

Recent updates

Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

Consensus EPS estimates fall by 33%

Royalty Pharma: Busy Putting Capital To Work

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Upcoming dividend of US$0.21 per share

Royalty Pharma plc Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21

First quarter dividend of US$0.21 announced

Royalty Pharma plc to Report Q2, 2024 Results on Aug 08, 2024

Royalty Pharma plc Declares Dividend for the Third Quarter of 2024, Payable on September 13, 2024

Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director

Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director

Consensus EPS estimates fall by 10%

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.77 in 1Q 2023)

Upcoming dividend of US$0.21 per share

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Royalty Pharma plc, Annual General Meeting, Jun 06, 2024

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Fourth quarter dividend of US$0.21 announced

Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024

Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Consensus EPS estimates increase by 79%

Royalty Pharma: Solid Operational Performance

Full year 2023 earnings released: EPS: US$2.54 (vs US$0.098 in FY 2022)

Upcoming dividend of US$0.21 per share at 2.9% yield

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Royalty Pharma plc to Report Q4, 2023 Results on Feb 15, 2024

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024

Consensus EPS estimates increase by 68%

Director notifies of intention to sell stock

Director recently sold US$7.1m worth of stock

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Director recently sold US$19m worth of stock

Director notifies of intention to sell stock

Consensus EPS estimates increase by 94%

Third quarter 2023 earnings released: EPS: US$0.16 (vs US$0.33 in 3Q 2022)

Upcoming dividend of US$0.20 per share at 2.9% yield

Consensus EPS estimates increase by 55%

Consensus EPS estimates increase by 15%

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Upcoming dividend of US$0.20 per share at 2.6% yield

Second quarter 2023 earnings released: EPS: US$0.51 (vs US$0.70 in 2Q 2022)

Insufficient new directors

Royalty Pharma plc Declares Dividend on Class A Ordinary Shares for the Third Quarter of 2023, Payable on September 15, 2023

Executive VP & CFO recently sold US$2.3m worth of stock

Executive VP & CFO notifies of intention to sell stock

Founder recently bought US$3.8m worth of stock

Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023

Insider recently sold US$6.5m worth of stock

Insider notifies of intention to sell stock

Director notifies of intention to sell stock

Founder recently bought US$7.7m worth of stock

Consensus EPS estimates increase by 243%

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of US$0.20 per share at 2.4% yield

First quarter 2023 earnings released: EPS: US$0.77 (vs US$0.12 in 1Q 2022)

Consensus EPS estimates increase by 46%

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Director recently sold US$5.1m worth of stock

Insider recently sold US$932k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations